| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
ALZ-801 (ALZ801; BLU-8499; NRM-8499) is an orally bioavailable, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation with the potential for treating Alzheimer's disease (AD). ALZ-801 is a prodrug of tramiprosate with improved PK/pharmacokinetic properties and gastrointestinal tolerability.
| ln Vivo |
The mean AUCt values of ALZ-801 (Alabama Drug; 172 mg/kg; single dose) were 58, 758, and 5841 ng/mL.h in plasma and brain, respectively. ALZ-801: The ratios of trimiprost in the waist and midbrain of CD-1 mice were 1.8 and 3.1, respectively [1].
|
|---|---|
| References |
|
| Molecular Formula |
C8H18N2O4S
|
|---|---|
| Molecular Weight |
238.3045
|
| Exact Mass |
238.098
|
| CAS # |
1034190-08-3
|
| Related CAS # |
3687-18-1;
|
| PubChem CID |
25008296
|
| Appearance |
White to off-white solid powder
|
| LogP |
-3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
15
|
| Complexity |
294
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(CCNC([C@H](C(C)C)N)=O)S(=O)(=O)O
|
| InChi Key |
NRZRFNYKMSAZBI-ZETCQYMHSA-N
|
| InChi Code |
InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
|
| Chemical Name |
(S)-3-(2-Amino-3-methylbutanamido)propane-1-sulfonic acid
|
| Synonyms |
BLU 8499 ALZ 801 NRM8499 BLU8499ALZ-801 NRM-8499BLU-8499ALZ801 NRM 8499
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~30 mg/mL (~125.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (419.64 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1964 mL | 20.9820 mL | 41.9639 mL | |
| 5 mM | 0.8393 mL | 4.1964 mL | 8.3928 mL | |
| 10 mM | 0.4196 mL | 2.0982 mL | 4.1964 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04585347 | Completed | Drug: ALZ-801 170 mg Fasting Drug: ALZ-801 205 mg Fasting Drug: ALZ-801 205 mg After Food Drug: ALZ-801 342 mg Fasting |
Alzheimer Disease | Alzheon Inc. | 2015-09-16 | Phase 1 |
| NCT04157712 | Completed | Drug: ALZ-801 or matching placebo | Alzheimer Disease | Alzheon Inc. | 2015-09-26 | Phase 1 |
| NCT04693520 | Active, not recruiting | Drug: ALZ-801 | Early Alzheimer's Disease | Alzheon Inc. | 2020-09-30 | Phase 2 |
| NCT06304883 | Enrolling by invitation | Drug: Experimental: ALZ-801 | Early Alzheimer's Disease | Alzheon Inc. | 2024-04-02 | Phase 3 |
| NCT04770220 | Completed | Drug: Experimental: ALZ-801 Drug: Placebo Comparator: Placebo |
Early Alzheimer's Disease | Alzheon Inc. | 2021-05-19 | Phase 3 |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
